High Hormone Therapy Use Post-Endometriosis Surgery

Byalsapataca
🟢
Peer-Reviewed Research

High Hormone Therapy Use After Surgery for Endometriosis Signals Clinical Need

More than 94% of women under age 45 with endometriosis who underwent a hysterectomy and removal of ovaries used menopausal hormone therapy (MHT) afterward. This data comes from a Finnish registry study that tracked over 11,000 women between 1996 and 2019. For women over 45 with endometriosis, the rate was 73%. Both figures were significantly higher than in a reference group of women without endometriosis. Researchers from the University of Helsinki and Helsinki University Hospital reported these findings, highlighting the near-universal need for hormone replacement in this patient group. The study also observed a clear shift toward prescribing combined estrogen-progestin therapy over time, reflecting updated clinical guidelines.

What Hormone Replacement Therapy Is and Why It Is Used

Hormone replacement therapy (HRT), also called menopausal hormone therapy (MHT), is treatment with estrogen, often combined with progestogen, to relieve symptoms caused by declining hormone levels. The primary goal is to replace hormones the body no longer produces in sufficient amounts, most commonly during the menopausal transition.

HRT Addresses a Core Physiological Change

Estrogen and progesterone are fundamental regulators of numerous bodily systems. Their decline affects thermoregulation, bone metabolism, cardiovascular function, skin integrity, and brain chemistry. HRT aims to restore a baseline level of these hormones to mitigate the direct effects of their absence.

The Two Main Categories of Therapy

HRT is broadly divided into two types based on formulation:

  • Estrogen-only Therapy (ET): Used exclusively for women who have had a hysterectomy (removal of the uterus). Adding progestogen is unnecessary because there is no risk of endometrial cancer from unopposed estrogen.
  • Combined Estrogen-Progestogen Therapy (EPT): Standard for women with a uterus. The progestogen protects the uterine lining from hyperplasia, a precursor to cancer, which can occur with estrogen alone.

These hormones can be delivered via oral tablets, skin patches, gels, sprays, or vaginal preparations.

Scientific Evidence: HRT for Symptom Relief and Beyond

The most robust evidence supports HRT as the most effective treatment for vasomotor symptoms like hot flashes and night sweats. Its benefits extend to other areas, though the risk-benefit profile must be individually assessed.

Relief of Core Menopausal Symptoms

Randomized controlled trials consistently show that HRT reduces the frequency and severity of hot flashes by about 75%. It also effectively treats vaginal dryness, reduces the risk of recurrent urinary tract infections, and can improve sleep quality disrupted by night sweats. For a detailed review of treatments for these symptoms, see our article on Effective Hot Flashes Treatments: Evidence-Based Guide.

Prevention of Osteoporosis

Estrogen is a key player in maintaining bone density. HRT started before age 60 or within ten years of menopause reduces postmenopausal bone loss and lowers fracture risk. This benefit diminishes after stopping therapy.

Potential Impacts on Skin, Mood, and Cognition

Research indicates estrogen influences skin collagen, thickness, and hydration. A 2026 review by Lephart and Draelos outlined the role of estrogen in skin aging. Observational studies also suggest HRT may be associated with a lower risk of depressive symptoms during the menopausal transition and could have a protective effect on certain aspects of cognitive function, though these areas require more conclusive long-term data.

HRT in Complex Clinical Situations: The Case of Endometriosis

The Finnish registry study provides real-world data on a specific and challenging clinical scenario: HRT use after hysterectomy for endometriosis.

Endometriosis Creates a Therapeutic Dilemma

Endometriosis is an estrogen-dependent condition. Symptoms often resolve after natural menopause due to lower estrogen levels. However, surgical menopause—removal of ovaries in young women—creates an immediate, severe deficit. Clinicians must balance the profound symptoms of sudden menopause against the theoretical risk that HRT could reactivate residual endometriosis lesions.

Registry Data Shows High Utilization and Changing Patterns

The study by Sipilä et al. found that 94.3% of young women (≤45 years) with endometriosis and surgical menopause used MHT. This suggests that for most patients and doctors, the benefits of treating surgical menopause symptoms outweigh concerns about disease recurrence. The type of therapy prescribed has evolved: while estrogen-only was most common, the use of combined estrogen-progestin therapy increased significantly over the study period. International guidelines now often recommend adding progestogen for its potential to suppress any remaining endometriosis tissue.

Gaps in Long-Term Outcome Data

The authors explicitly note a lack of specific scientific knowledge on the long-term benefits and risks of HRT in women with endometriosis history. The high usage rates they documented underscore the urgency for studies focused on this population’s health outcomes over decades.

Practical Considerations: Risks, Timing, and Personalization

HRT is not suitable for everyone. A personalized assessment, considering age, health history, and symptom severity, is essential.

Understanding the Risk Profile

For most healthy women under 60 starting HRT for symptom relief, the absolute risks are low. The therapy is associated with a small increased risk of venous thromboembolism (mainly with oral forms), breast cancer (with combined therapy used for more than 5 years), and stroke. The risk of endometrial cancer is eliminated by using combined therapy in women with a uterus. A detailed discussion of benefits and risks can be found in our HRT Guide: Evidence, Benefits, and Menopause Risks.

The Importance of Timing and “Window of Opportunity”

Current evidence supports the concept that starting HRT around the time of menopause (before age 60 or within 10 years of menopause) may offer the best balance of benefits and risks, particularly for cardiovascular and cognitive health. Starting therapy many years after menopause is not generally recommended for long-term prevention.

Creating an Individualized Treatment Plan

A treatment plan should specify:

  • The type of hormones (estrogen only or combined).
  • The delivery method (patch, gel, pill).
  • The dose (starting low and adjusting as needed).
  • A review timeline (usually annually).
  • A planned duration, recognizing that treatment for symptom relief can often be shorter-term.

Actionable Takeaways for Patients and Clinicians

Evidence supports HRT as a primary tool for managing the menopausal transition, but its application requires careful thought.

For patients experiencing disruptive symptoms like severe hot flashes, vaginal dryness, or sleep disturbance, HRT is likely the most effective medical intervention. Discussing personal risk factors—such as family history of breast cancer, personal history of blood clots, or liver disease—with a doctor is the first step.

For clinicians, the high rates of HRT use in complex cases like endometriosis, as shown in the Finnish study, confirm that symptom burden often drives treatment decisions. Staying informed on evolving guidelines, such as the increasing preference for combined therapy in endometriosis patients, is important. Acknowledging the lack of long-term data for specific subgroups should inform patient counseling and motivate shared decision-making.

Non-hormonal strategies, including lifestyle modifications and certain medications, can also play a role, either as adjuncts or alternatives. For more on this, consider our Menopause Diet Guide: Evidence-Based Nutrition Strategies.

Key Takeaways

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *